Macronex Inc. said it has received two Phase I small businessinnovation research (SBIR) grants from the National Institute ofAllergy and Infectious Diseases of the National Institute ofHealth.

One grant will be used to conduct preclinical studies of a classof proprietary peptides and proteins that the Research TrianglePark, N.C., company is developing as immunoregulating agentswith potential applications in the treatment of inflammatoryand autoimmune conditions and graft rejection, said GeorgeCianciolo, Macronex's executive vice president for research anddevelopment.

The second grant will support investigation as potentialtherapeutics of a class of unique, derivatized amino acids thathave demonstrated immunosuppressive activities in murinemodels.

(c) 1997 American Health Consultants. All rights reserved.